PrEP

Pre-exposure prophylaxis involves people who do not have HIV taking antiretroviral drugs when they are at risk of exposure to HIV in order to prevent infection. The drugs are usually taken as pills (oral PrEP). Visit our Microbicides section for information on the development of topical PrEP products.

Topics in this section

PrEP: latest news

PrEP resources

PrEP features

PrEP news from aidsmap

More news

PrEP news selected from other sources

  • Market for HIV Prevention Drugs May More Than Double, Citi Says

    An experimental drug from Merck & Co may lead the way in the U.S. market, Citi said. Baum estimates MK-8591 may reach sales of $7 billion in HIV. Of that total, $3.5 billion may come from pre-exposure prophylaxis, or PrEP, as the preventative treatments are called.

    21 July 2019 | Bloomberg

  • Trial Pairs PrEP With Behavioral Intervention to Prevent HIV in Drug Users

    Yale University investigators are leading a trial that is testing a bio-behavioral intervention’s ability to improve pre-exposure prophylaxis (PrEP) adherence and reduce the risk of HIV acquisition in individuals with opioid dependency, a population experiencing new outbreaks of HIV.

    15 July 2019 | Contagion Live

  • Insurance Will Soon Cover HIV Prevention, But Many People Who Need it Still Won't Have Access

    When Corey Walsh began using the drug Truvada, the pills were free but the quarterly lab tests and doctors' visits cost almost $400.

    11 July 2019 | Vice

  • NHS England recommends uncapped PrEP trial access

    NHS England have announced five steps towards better access to the HIV prevention drug PrEP, including recommending removing the capped number of places on the ongoing IMPACT Trial. This follows a meeting yesterday between Simon Stevens, chief executive of NHS England, NAT (National AIDS Trust), Terrence Higgins Trust, and PrEPster.

    08 July 2019 | National Health Executive

  • HIV diagnoses in Australia drop to lowest number in 18 years

    Australia continues to lead the world in HIV prevention and in 2018 recorded the lowest number of HIV diagnoses since 2001. According to a report released today by the Kirby Institute at UNSW Sydney, last year there were 835 HIV diagnoses across the country, which represents a decline of 23% over five years.

    03 July 2019 | University of New South Wales

  • CytoDyn Signs Groundbreaking Memorandum of Understanding with Thai Red Cross AIDS Research Centre to Study Pre-Exposure Prophylaxis Use of Leronlimab (PRO 140) in People at High Risk of Acquiring HIV

    “The rationale for the use of leronlimab as PrEP is grounded in the long-standing observation that individuals deficient for the CCR5 co-receptor are nearly completely resistant to sexual transmission of HIV,” said Dr. Jonah Sacha, Associate Professor of the Oregon Health & Science University. Dr. Sacha continued, “Given the difficulties many patients face with adherence to daily oral antiretroviral therapy drugs as PrEP, once-weekly leronlimab as PrEP could be transformative in slowing the epidemic.”

    20 June 2019 | CytoDyn press release

  • My PrEP Story: Leander (part 3)

    I recently chatted with someone on Grindr who told me he “only did safe”. I asked him if that meant he preferred to use condoms. He said that’s obviously what ‘safe’ meant.

    17 June 2019 | Prepster

  • Ireland: PrEP programme to reduce HIV rates to be rolled out later this year

    THE PrEP HIV prevention programme will be implemented in 2019, Health Minister Simon Harris said today. “We want to reduce the number of new HIV diagnoses in Ireland. Increasing the availability of PrEP will help us to do so. This report not only confirms that PrEP can help to prevent HIV amongst those who are high risk, it also shows how a PrEP programme could save money,” said Harris.

    17 June 2019 | Journal.ie

  • Ireland: HIV programme ‘will be undermined’ by lack of capacity

    Thousands of people are being turned away from sexual health clinics across the Republic, which will undermine a programme for preventing HIV due to be introduced later this year, according to Fianna Fáil. The PrEP (pre-exposure prophylaxis) HIV prevention programme is being implemented by the Government following advice from the State’s health watchdog that it would be safe and cost-effective.

    17 June 2019 | Irish Times

  • The truth is you can afford the medication that prevents HIV. Here’s how.

    It’s not the cost of PrEP that keeps more patients from accessing it; it’s the lack of awareness and the daunting nature of our complicated healthcare system.

    24 May 2019 | LGBTQ Nation
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.